

**USC**

UNIVERSITY  
OF SOUTHERN  
CALIFORNIA

Keck School of Medicine  
University of Southern California

June 18, 2007

**Department of Medicine**

**Edward D. Crandall, Ph.D., M.D.**  
Chair, Department of Medicine  
Kenneth T. Norris, Jr.  
Chair of Medicine  
Hastings Professor of  
Medicine  
Director, Will Rogers  
Institute Pulmonary  
Research Center


Allen F. Gant  
CEO and Board Chair  
BioMarck Pharmaceuticals  
2619 St. Mary's Street  
Raleigh, NC 27609

Dear Mr. Gant:

Thank you for the opportunity to comment on Dr. Kenneth Adler's work and the promise of MARCKS protein in airway mucin secretion and inflammation associated with COPD and other obstructive airways diseases. Dr. Adler has a national and international reputation in pulmonary research. The scientific pulmonary community is well aware of his extensive work demonstrating that peptides directed against a particular molecule in cells lining the respiratory airways and cells associated with inflammation are effective inhibitors of excess mucus secretion and inflammation in the airways, respectively. Dr. Adler presented an update on some of his work at a research seminar here at USC in December of 2006. I and other members of the audience were, as is usual with Ken's work, very impressed by the careful attention to scientific detail, the novelty and innovation represented by the science, and the implications for future therapeutic maneuvers. Being aware of the technology involved, the fact that there is no current treatment that targets directly both mucus and inflammation in COPD, and that current drugs offer only slight improvement in COPD patients, the BioMarck drug could be among the most important discoveries in the field of airway inflammation.

Dr. Adler has been a leader in research in airway biology for decades. His contributions are widely recognized and have had major impacts on his fields. Airway biology is currently one of the most important areas of lung research, and his recent studies are extremely significant. I have long thought that numerous patients could benefit from his discovery of MARCKS protein's role in airway inflammation and mucus secretion is enormous. All the recent advances in Dr. Adler's study of this protein and his work with BioMarck increase my expectations for successful therapeutic application.

Sincerely yours,



Edward D. Crandall

2020 Zonal Avenue  
IRD 620  
Los Angeles,  
California 90033  
Tel: 323 226 7593  
Fax: 323 226 2899  
e-mail:  
ecrandal@hsc.usc.edu

T:\EDC\Recomm Ltrs\Adler BioMarck ltr.doc